nanoparticles
| 3 min read
A team from Stanford and NYU shows how Bacteroides fragilis can activate pain pathways, revealing a new microbial culprit in digestive disease.
| 1 min read
Operational scale-up accelerates global growth strategy to increase regional access and technical support
| 3 min read
Researchers designed a nanoparticle that inactivated a wide range of COVID-19 strains, potentially offering a broad-spectrum therapeutic approach.
| 4 min read
Magnetic carbon nanotubes treat drug-resistant glioblastoma in mice, but hurdles remain for human translation.
| 10+ min read
Eye injections are the only way to treat diabetic retinopathy, but many refuse to get them. Now, eye drops and pills are on their way.
| 2 min read
Researchers simultaneously increased the potency of a cancer drug while reducing both the required dose and the side effects, all by using a surprising new drug delivery vehicle: bacteria.
Available on Demand
Join a panel of experts as they discuss nanoparticle technology and key considerations for nanoparticle-based drug delivery.
| 3 min read
Nanoparticles fuse with cells to deliver their gene or RNA therapy cargo, but some are better shuttles than others. Now, scientists have developed a way to find the best nanoparticles for the job.
| 4 min read
Scientists and clinicians discussed their solutions for overcoming the challenge of getting past the blood-brain barrier in DDN’s first seminar.
| 4 min read
Nanoparticles that successfully deliver drugs in mice often fail in humans. To understand how nanoparticles fare across different model species, scientists developed a high-throughput system to screen nanoparticles in mice with humanized livers with the hope of better predicting nanoparticles that work in humans.
